<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887406</url>
  </required_header>
  <id_info>
    <org_study_id>104865</org_study_id>
    <nct_id>NCT00887406</nct_id>
  </id_info>
  <brief_title>Study of GSK961081 in Healthy Volunteer Subjects</brief_title>
  <official_title>A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetic Profile and Pharmacodynamics of Single and Repeat Inhaled Doses of GSK961081 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic&#xD;
      obstructive pulmonary disease (COPD). This study is the first clinical study in humans. The&#xD;
      purpose of this study is to determine the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of GSK961081 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2005</start_date>
  <completion_date type="Actual">October 4, 2006</completion_date>
  <primary_completion_date type="Actual">October 4, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and tolerability (adverse events, clinical laboratory safety tests, cardiac monitoring, vital signs (including postural changes in blood pressure), 12-lead ECG parameters including QTc(b) and QTc(f), blood glucose and serum potassium).</measure>
    <time_frame>Pre and post-dose on Days 1, 4 and 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maxiumum and weighted mean (over 0-8 hours post-dose) for systolic and diastolic blood pressure, heart rate, QTc(F), QTc(B), plasma glucose and serum potassium</measure>
    <time_frame>Days 1, 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>specific airway conductance (sGaW)</measure>
    <time_frame>pre and post-dose on Days 1, 4 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Pre and post-dose on Days 1, 4 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 100mcg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK961081 300mcg or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 15mcg SD</intervention_name>
    <description>Single dose delivered via solution for nebulisation</description>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>GSK961081 200mcg SD</other_name>
    <other_name>GSK961081 50mcg SD</other_name>
    <other_name>GSK961081 300mcg SD</other_name>
    <other_name>GSK961081 100mcg SD</other_name>
    <other_name>GSK961081 3mcg SD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 3mcg SD</intervention_name>
    <description>single dose delivered via nebulsier</description>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 50mcg SD</intervention_name>
    <description>single dose delivered via solution for nebulisation</description>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SD</intervention_name>
    <description>single dose via nebuliser</description>
    <arm_group_label>Cohort 1, Period 2</arm_group_label>
    <arm_group_label>Cohort 1, period 1</arm_group_label>
    <arm_group_label>Cohort 1, period 3</arm_group_label>
    <arm_group_label>Cohort 1, period 4</arm_group_label>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 100mcg SD</intervention_name>
    <description>single dose delivered via solution for nebulisation</description>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 200mcg SD</intervention_name>
    <description>single dose via nebuliser</description>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 300mcg SD</intervention_name>
    <description>single dose via nebuliser</description>
    <arm_group_label>Cohort 2, period 1</arm_group_label>
    <arm_group_label>Cohort 2, period 2</arm_group_label>
    <arm_group_label>Cohort 2, period 3</arm_group_label>
    <arm_group_label>Cohort 2, period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 100mcg RD</intervention_name>
    <description>repeat dose via nebuliser</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>GSK961081 100mcg SD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK961081 300mcg RD</intervention_name>
    <description>repeat dose vai nebuliser</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo RD</intervention_name>
    <description>repeat dose via nebuliser</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males aged between 18 and 50 years.&#xD;
&#xD;
          -  Body mass index within the range 18.5-29.9 kilograms/meter2 (kg/m2).&#xD;
&#xD;
          -  Forced Expiratory Volume in 1 second (FEV1) &lt;80% predicted and a FEV1/ Forced Vital&#xD;
             Capacity (FVC) ratio &lt;0.7&#xD;
&#xD;
          -  Response to Salbutamol defined as: an increase in sGAW of &gt;15% over pre-dose baseline&#xD;
             within 2 h following administration of 400 mcg Salbutamol by MDI inhaler OR: a&#xD;
             documented increase in sGAW of &gt;15% over pre-dose baseline within 2 h following&#xD;
             administration of 400 mcg Salbutamol by MDI inhaler within 6 months of screening.&#xD;
&#xD;
          -  Response to Ipratropium bromide defined as: an increase in sGaw of &gt;25% over pre-dose&#xD;
             baseline within 2 h following 80 mcg Ipratropium bromide; OR: a documented increase in&#xD;
             sGaw of &gt;25% over pre-dose baseline 2 h following administration of 80 mcg Ipratropium&#xD;
             bromide within 6 months of screening.&#xD;
&#xD;
          -  A signed and dated written informed consent is obtained for the subject&#xD;
&#xD;
          -  The subject is able to understand and comply with the protocol requirements,&#xD;
             instructions and protocol-stated restrictions.&#xD;
&#xD;
          -  Subjects who are current non-smokers who have not used any tobacco products in the&#xD;
             6-month period preceding the screening visit and have a pack history of &gt; or = 10 pack&#xD;
             years.&#xD;
&#xD;
        [number of pack years = (number of cigarettes per day/20) x number of years smoked]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality identified at the screening medical assessment&#xD;
             (physical examination/medical history), clinical laboratory tests, or ECG (12-lead or&#xD;
             Holter).&#xD;
&#xD;
          -  A history of breathing problems (i.e. history of asthmatic symptoms). Screening lung&#xD;
             function tests (FEV1, FVC and sGaw) will be performed to confirm normal lung function&#xD;
             parameters.&#xD;
&#xD;
          -  A mean QTc(B) and QTc(F) value at screening &gt;430msec, the 3 screening ECGs are not&#xD;
             within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is&#xD;
             not suitable for QT measurements (e.g. poorly defined termination of the T wave).&#xD;
&#xD;
          -  A supine blood pressure that is persistently higher than 140/90 millimetres of mercury&#xD;
             (mmHg) at screening.&#xD;
&#xD;
          -  A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.&#xD;
&#xD;
          -  The subject has donated a unit of blood within the 90 days or intends to donate within&#xD;
             90 days after completing the study.&#xD;
&#xD;
          -  A history of claustrophobia such that they may not tolerate plethysmography&#xD;
             measurements.&#xD;
&#xD;
          -  The subject is currently taking regular (or course of) medication whether prescribed&#xD;
             or not, including vitamins and herbal remedies such as St John's Wort.&#xD;
&#xD;
          -  The subject has used prescription or non-prescription drugs, including vitamins,&#xD;
             herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if&#xD;
             the drug is a potential enzyme inducer) or 5 half-lives (which ever is longer) prior&#xD;
             to the first dose of study medication, unless in the opinion of the Investigator and&#xD;
             Sponsor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  The subject has participated in a clinical study with another New Chemical Entity&#xD;
             (NCE) within the past 112 days or a clinical study with any other drug during the&#xD;
             previous 84 days.&#xD;
&#xD;
          -  The subject is infected with the Hepatitis B, Hepatitis C, or HIV virus.&#xD;
&#xD;
          -  The subject has a positive pre-study urine cotinine/ breath carbon monoxide test,&#xD;
             urine drug/urine alcohol screen. A minimum list of drugs that will be screened for&#xD;
             include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.&#xD;
&#xD;
          -  A history of regular alcohol consumption exceeding weekly intake of alcohol greater&#xD;
             than 28 units, or an average daily intake of greater than 4 units.&#xD;
&#xD;
          -  Are unable to use the Prodose AAD nebuliser device correctly.&#xD;
&#xD;
          -  An unwillingness of subjects to abstain from sexual intercourse with pregnant or&#xD;
             lactating women; or an unwillingness of the subject to use a condom/spermicide in&#xD;
             addition to having their female partner use another form of contraception such as IUD,&#xD;
             diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal&#xD;
             implants or tubal ligation if the woman could become pregnant from the time of the&#xD;
             first dose study medication until 90 days post-dose.&#xD;
&#xD;
          -  The subject has a history of drug or other allergy, which, in the opinion of the&#xD;
             responsible physician, contraindicates their participation.&#xD;
&#xD;
          -  The subject has a history of hypersensitivity to Salbutamol or Ipratropium bromide,&#xD;
             and for those subjects in cohorts III and IV, hypersensitivity to a beta-blocker.&#xD;
&#xD;
          -  The subject has had a lower respiratory tract infection within 4 weeks of study start&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>first time in human study</keyword>
  <keyword>COPD</keyword>
  <keyword>long-acting bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104865</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

